InMed Pharmaceuticals, a leader in the development and commercialization of rare cannabinoids and proprietary small molecule drug candidates, has recently been granted three new patents in the U.S. These patents cover a formulation and method of use for treating epidermolysis bullosa and related connective tissue disorders, biosynthesis manufacturing processes, and an ocular drug delivery formulation. This development brings InMed's total patent families to 13, encompassing new chemical entities, formulations, manufacturing processes, and methods of use.
Eric A. Adams, President and CEO of InMed Pharmaceuticals, expressed satisfaction with the patent issuances, highlighting their role in increasing the commercial value of the company's programs and safeguarding its drug research and development endeavors. The company is dedicated to further expanding its patent portfolio to protect its innovative drug candidates, manufacturing methods, formulations, and applications, aiming to address diseases with significant unmet medical needs.
For more details on this announcement, visit https://cnw.fm/r84IM.
